CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Ablation Treatmentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06175234
NCT06175234N/ACompleted
CompareCT.gov

A Study Evaluating the User Experience With the FARAVIEW™ Technology of the RHYTHMIA HDx™ Mapping System When Used With the FARAWAVE NAV™ Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation

Boston Scientific Corporation·interventional·Posted Dec 18, 2023·Updated Sep 17, 2025

In Brief

A clinical study evaluating Ablation Treatment for Atrial Fibrillation and 2 related conditions. Completed, enrolled 50 participants across 3 sites in 3 countries.

Detailed Summary

The purpose of this study is to gather data regarding the utilization of the FARAVIEW™ feature of the RHYTHMIA HDx Mapping System when used in conjunction with the FARAWAVE NAV Pulsed Field Ablation catheter in subjects undergoing catheter-based endocardial mapping and catheter-based ablation treatment of Atrial Fibrillation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
CountriesCzechia, Ireland, Spain
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedDec 18, 2023
Enrollment StartApr 3, 2024
Primary CompletionMay 15, 2025
Study CompletionJun 6, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.5 years ago

Interventions

Ablation Treatmentdevice

For subjects with paroxysmal AF, Pulmonary Vein Isolation will be performed with the FARAWAVE NAV catheter. For subjects with persistent AF, left atrial posterior wall isolation (PWI) may also be performed at the discretion of the investigator, with the FARAWAVE NAV PFA catheter.